Editor Ben Weinberg

About the Author Editor Ben Weinberg

Feltl Maintains Buy On Immersion Corporation Amid Potential Partnership With Apple

In a research note issued today, Feltl and Company analyst Jeffrey Schreiner maintained a Buy rating on Immersion Corporation (IMMR) with a price target …

Topeka Is Confident In Google After Release Of iWatch

In a research note released Thursday, Topeka Capital analyst Victor Anthony maintained a Buy rating on shares of Google Inc. (GOOG), with a price target of $657, following Google’s Developers …

Roth Capital Reaffirms Neutral Rating On Zagg As Concerns Rise Over Long-Term Viability

In a research note released today, Roth Capital analyst Dave King reaffirms a Neutral rating on Zagg Inc. (ZAGG) with a price target of …

H.C. Wainwright Assumes Buy On OXiGENE, Reduces Price Target To $6

In a research note released today, H.C.

H.C. Wainwright Initiates Buy On Cesca Therapeutics; Sets $5 Price Target

In a research noted released today, H.C.

Topeka Maintains Buy Rating On IAC As Aereo Violates Copyright Laws

In a research note released yesterday, Topeka Capital analyst Victor Anthony maintained a Buy rating on IAC/InterActiveCorp (IACI) and a price target of $98 following the decision of …

Roth Capital Reiterates Buy On Align Technology Following Danaher’s Investor Day

In a research note issued today, Roth Capital analyst Chris Lewis reiterated a “Buy” rating on Align Technology (ALGN) and a price target of $66 following Danahers Corporation’s (DHR) …

Roth Capital Maintains A Buy On LeapFrog Following Announcement Of Two New Tablets

In a report issued today, Roth Capital analyst Dave King maintained a “Buy” rating on LeapFrog Enterprises Inc. (LF) and a price target of $7.

Despite Deferral Of Underground Mine, Canaccord Raises Price Target For Pan American Silver

Canaccord analyst John Kratochwil yesterday reiterated a “Hold” rating on Pan American Silver Corp (PAAS) and increased his price target to $18.75 (from $17.

Roth Capital Reiterates Buy On Ligand Pharmaceutical Following Partnership With TG

In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceutical (LGND) and a price target of $92.00 following …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts